GO
Loading...

Enter multiple symbols separated by commas

Pfizer Inc

More

  • Novel US cancer study will test precision medicine Monday, 1 Jun 2015 | 9:55 AM ET

    The National Cancer Institute's NCI-MATCH trial will be a massive precision medicine experiment at more than 2,400 sites around the country. Douglas Lowy, the Cancer Institute's acting director. Details of the study were revealed Monday at an American Society of Clinical Oncology conference in Chicago.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed lower on the last trading day of the month, as investors digested data and remained cautious on continued concerns about Greece.

  • WASHINGTON, May 28- The U.S. Food and Drug Administration on Thursday approved the first drug to treat a rare, progressive lung disease that mainly affects women of childbearing age. The drug, Rapamune, known chemically as sirolimus, is made by Pfizer Inc and is designed to treat lymphangioleiomyomatosis, a disease that causes lung damage and affects only two to...

  • Cellectis jumps 14% on talks of sale to Pfizer Thursday, 28 May 2015 | 3:57 PM ET
    French CEO of Cellectis, a biotechnology company, Andre Choulika.

    Pfizer reportedly approached Cellectis with a deal that could value it at about $1.64 billion, the Financial Times reported.

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks closed about 1 percent lower as investors eyed renewed strength in the dollar and data that could strengthen the case for a rate hike.

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • LONDON, May 26- Boston- based PureTech Health plans to raise $160 million in a London listing, filling its coffers to fund product development and delivering a vote of confidence in the British life sciences sector. The move by the U.S. health technology firm follows a similar decision by California- based drug discovery group Verseon to raise $100 million in...

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...

  • Cramer: Mergers that could unlock riches for you Thursday, 21 May 2015 | 6:35 PM ET
    Pedestrians walk by a CVS store in San Francisco.

    Jim Cramer considers this group to be the single best out there, and it's ready to pull off some big deals.

  • Early movers: BBY, OCR, HPQ, PFE, NKE & more Thursday, 21 May 2015 | 7:51 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, May 19- Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Recommendations for marketing approval by its Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.

  • Goldman: Market's going nowhere for a year Tuesday, 19 May 2015 | 7:34 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Goldman Sachs analysts believe the S&P may climb a bit higher before its ascent is over for the next 12 months.

  • CEOs love buying stock with your money, not own Monday, 18 May 2015 | 11:35 AM ET
    Senior exec stocks

    As CEOs buy a record amount of stock with shareholder money, they're keeping their wallets in their pockets when it comes to buying shares on their own.

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET
    Biotech

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • *Tie-up with Montreal scientists on heart disease genes. LONDON, May 13- AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease. To redress the balance, AstraZeneca said on Wednesday it had signed two deals, one with Abbott Laboratories for a diagnostic test...

  • US companies hoarding $1 trillion in cash Monday, 11 May 2015 | 2:10 AM ET
    US dollars

    Just five US companies are hoarding nearly half a trillion dollars as the country’s tax code and a tepid global economy deter firms from spending.

  • NEW YORK, May 11- It wasn't long ago that politics, like religious orientation or sexual preference, was a taboo topic in the American workplace. The Washington trade group, which has offices across the street from the White House, helps firms such as Wal-Mart, Halliburton and Lockheed Martin mobilize employees on policy issues important to the companies.